Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 248 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Rheumatoid Arthritis RA Clear all
Terminated Phase 2 Interventional Results available

A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

NCT03001219
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Anti-TNF-alpha, Methotrexate, Placebo, RO7123520
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 11, 2026, 1:54 AM EDT
Recruiting Phase 3 Interventional

RA-PRO PRAGMATIC TRIAL

NCT04692493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
targeted synthetic DMARD class, non-TNFi-biologic class
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
48
States / cities
Auburn, Alabama • Birmingham, Alabama • Peoria, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 11, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00531817
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo, Permitted DMARDs
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
156
States / cities
Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 11, 2026, 1:54 AM EDT
Terminated Phase 3 Interventional Results available

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

NCT05246280
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TC99m-tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Beverly Hills, California • San Francisco, California • Avon Park, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 11, 2026, 1:54 AM EDT
Completed Phase 1 Interventional

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs

NCT04286789
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Low dose ORTD-1, Low dose vehicle control, High dose ORTD-1, High dose vehicle control
Drug
Lead sponsor
Oryn Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Los Angeles, California • Tustin, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 11, 2026, 1:54 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

NCT07607964
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
ABBV-519
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Anniston, Alabama • Tustin, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 11, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

NCT01377012
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Secukinumab (AIN457), Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
39
States / cities
Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 11, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

NCT00122382
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, placebo, methotrexate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Huntington Beach, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Oct 11, 2026, 1:54 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

NCT03682705
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Elsubrutinib, Upadacitinib, Placebo for elsubrutinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
78
States / cities
Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 11, 2026, 1:54 AM EDT
Withdrawn Not applicable Interventional

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

NCT02053727
View directory record Official record
Conditions
Rheumatoid Arthritis, Chronic Hepatitis B
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 11, 2026, 1:54 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)

NCT00882024
View directory record Official record
Conditions
Active Rheumatoid Arthritis
Interventions
Tranilast, Placebo
Drug
Lead sponsor
Nuon Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Mesa, Arizona • Paradise Valley, Arizona • La Jolla, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Oct 11, 2026, 1:54 AM EDT
Active, not recruiting Not applicable Interventional

Probiotics in Adults With Rheumatoid Arthritis

NCT07304505
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Align Extra Strength Probiotic Supplement
Dietary Supplement
Lead sponsor
Ancilia Biosciences
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 11, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

NCT00753454
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 11, 2026, 1:54 AM EDT
Terminated Not applicable Interventional

The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis

NCT02078375
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Protein, Carbohydrate (Placebo), Resistance Exercise Program
Dietary Supplement · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years to 95 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 11, 2026, 1:54 AM EDT
Completed No phase listed Observational

Gene-Environment Interactions in Rheumatoid Arthritis Autoimmunity Disease Severity

NCT00594451
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 11, 2026, 1:54 AM EDT
Enrolling by invitation Not applicable Interventional

Ketogenic Diet in Rheumatoid Arthritis (RA)

NCT05799768
View directory record Official record
Conditions
Rheumatoid Arthritis, Inflammation, Obesity, Ketogenic Dieting, Metabolic Syndrome
Interventions
Ketogenic diet
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 11, 2026, 1:54 AM EDT
Active, not recruiting Not applicable Interventional

Long Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)

NCT04862117
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
Device
Lead sponsor
SetPoint Medical Corporation
Industry
Eligibility
22 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Aventura, Florida • Zephyrhills, Florida • Great Neck, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 11, 2026, 1:54 AM EDT
Recruiting No phase listed Observational

The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study

NCT07315997
View directory record Official record
Conditions
Rheumatoid Arthritis (RA, Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
high sensitivity cardiac troponin
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
35 Years to 79 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 11, 2026, 1:54 AM EDT
Completed Phase 3 Interventional

Treatment of Early RA: Minocycline in Combination With Methotrexate vs Methotrexate Alone

NCT00579644
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Combination of Minocycline and MTX or MTX alone, methotrexate
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 11, 2026, 1:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

NCT00254293
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept or Placebo (both as IV & SC solution), Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
5
States / cities
Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 11, 2026, 1:54 AM EDT
Terminated Phase 2 Interventional Results available

A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01

NCT00583557
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
belimumab
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 11, 2026, 1:54 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

NCT00805467
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib Disodium (R935788)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
35
States / cities
La Jolla, California • Palm Desert, California • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 11, 2026, 1:54 AM EDT
Completed Not applicable Interventional

Incorporating PRO Data Into RA Clinical Encounters Using Health IT

NCT06655077
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
RA PRO Dashboard
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 11, 2026, 1:54 AM EDT
Completed Phase 1 Interventional

Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis

NCT01055899
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
REGN88
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 11, 2026, 1:54 AM EDT